LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma.
BACKGROUND
Lysosomal protein transmembrane 4 β-35 (LAPTM4B-35), a novel oncoprotein that belongs to the mammalian 4-tetratransmembrane spanning protein superfamily, has been implicated in oncogenesis and cancer progression in several solid malignances. However, the expression of LAPTM4B-35 and its role in endometrial cancer progression remain unknown.


METHODS
We investigated the expression of the LAPTM4B-35 protein by immunohistochemistry in 30 normal endometrium specimens and 165 endometrial carcinomas and analyzed its correlation with various clinicopathologic features, including patient outcome.


RESULTS
LAPTM4B-35 immunoreactivity was overexpressed in endometrial carcinoma cases compared with normal endometrium (P < 0.001). High LAPTM4B-35 expression was found in 117 (70.91%) of these 165 carcinomas and was positively correlated with the International Federation of Gynecology and Obstetrics stage, histological grade, depth of myometrial invasion, lymph node metastasis, lymph vascular space involvement, and recurrence, but not with age and histological type. Patients with high LAPTM4B-35 expression had significantly poorer overall survival and disease-free survival compared with patients with low expression of LAPTM4B-35 (P = 0.001 and P = 0.002, respectively). Multivariate analysis showed that high LAPTM4B-35 expression was an independent prognostic factor for both overall survival and disease-free survival of patients with endometrial carcinoma (both P = 0.005).


CONCLUSIONS
These results showed that high LAPTM4B-35 expression was associated with progression and prognosis of endometrial carcinoma.
Meng
Fan-ling
FL
Departments of Gynecology, Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
Yin
Ming-zhu
MZ
Song
Hong-tao
HT
Yang
Hua
H
Lou
Ge
G
Zhou
Rou-li
RL
D000328:Adult; D000368:Aged; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000378:metabolism*; D004717:Endometrium / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008565:Membrane Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D015513:Oncogene Proteins / Q000096:biosynthesis*; D011379:Prognosis; D016019:Survival Analysis
C477083:LAPTM4B protein, human; D008565:Membrane Proteins; D015513:Oncogene Proteins